Tofacitinib was the first JAKi approved for the treatment of autoimmune diseases in humans.[31] It is an effective JAK1 and JAK3 inhibitor that also partially inhibits JAK2 and Tyk2.[32] However, its use for the treatment of SAVI has been limited. Here, JAK1 is linked to STING-associated vasculopathy with onset in infancy.